Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $5.93, for a total value of $130,460.00. Following the completion of the sale, the director directly owned 1,166,391 shares of the company’s stock, valued at $6,916,698.63. This trade represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock traded down $0.18 during trading hours on Monday, reaching $5.77. The company’s stock had a trading volume of 1,179,694 shares, compared to its average volume of 1,173,310. The company has a market capitalization of $802.03 million, a P/E ratio of -1.60 and a beta of 1.39. The stock’s fifty day simple moving average is $5.99 and its two-hundred day simple moving average is $5.53. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The firm’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.56) EPS. As a group, research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VIR. JPMorgan Chase & Co. lifted its holdings in shares of Vir Biotechnology by 1.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 449,518 shares of the company’s stock worth $2,567,000 after acquiring an additional 6,143 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Vir Biotechnology during the third quarter valued at about $38,000. Hudson Bay Capital Management LP grew its stake in shares of Vir Biotechnology by 31.0% during the third quarter. Hudson Bay Capital Management LP now owns 911,882 shares of the company’s stock valued at $5,207,000 after buying an additional 215,882 shares during the last quarter. Connective Capital Management LLC purchased a new position in shares of Vir Biotechnology in the third quarter worth about $431,000. Finally, Sender Co & Partners Inc. bought a new stake in shares of Vir Biotechnology in the 3rd quarter valued at about $247,000. 65.32% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on VIR shares. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.